ACADIA Pharmaceuticals Inc.

About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.

Overview of Receptor Cloning

Abstract: Receptors are generally categorized into four major superfamilies according to their structural and genetic similarities: steroid receptors, growth factor receptors, ionotropic receptors (i.e., ligand-gated ion channels), and metabotropic receptors (i.e., G protein-coupled receptors). This unit describes the methodology and critical issues for cloning receptors by several methods. Although cloning by protein purification was the first major method, it is now less frequently employed. The early, more tedious procedures broadened knowledge about receptors and established a strong foundation that has enabled the utilization of the newer approaches discussed in this unit, including: homology cloning by screening with oligonucleotides, DNA fragments or the products of direct polymerase chain reaction (PCR); expression cloning using function, ligand binding, and antibody recognition; and differential display techniques.

Design of a Highly Selective and Potent Class of Non‐planar Estrogen Receptor β Agonists.

Abstract: This describes the syntheses of various dibenzofurans and cycloheptanobenzofurans as estrogen receptor β agonists.

Real-World Medication Treatment Patterns for Long-Term Care Residents with Dementia-Related Psychosis.

Abstract: Objectives: This study evaluated treatment patterns and factors associated with medication treatment changes in residents with dementia-related psychosis in a long-term care (LTC) setting. Methods:...

Iron-Catalyzed Cross-Coupling of Imidoyl Chlorides with Grignard Reagents.

Abstract: A general, high yielding rapid iron-catalyzed cross-coupling reaction between Grignard reagents and imidoyl chlorides is described. These reactions are typically completed within 5 min, resulting in high yields of 71−96% using 5% iron catalyst in a THF−NMP solvent mixture. Functionalized imidoyl chlorides (e.g., R = CO2Me) gave excellent yields (89%).

Treatment Patterns With Antipsychotics in Long-Term Care Patients With Parkinson’s Disease Psychosis:

Abstract: This study assessed treatment change patterns in Parkinson's disease psychosis (PDP) residents receiving antipsychotic (AP) therapies in U.S. long-term care (LTC) facilities. Residents with PDP in LTC between 01/01/13 and 06/30/16 were identified with ≥1 claim of psychosis, hallucinations, or delusions after PD diagnosis. Treatment patterns were evaluated during the 12 months post index. We identified 864 PDP residents: 408 (47.2%) on AP therapy and 456 (52.8%) on no AP therapy. A total of 335 residents (82.1%) continued, 13 (3.2%) discontinued, 11 (2.7%) switched, and 49 (12.0%) augmented (used ≥2 APs) their index AP therapy. Based on the multivariate regression analysis, younger age, male gender, anemia, anxiolytic use or anxiety, sedatives/hypnotic use, bladder disorders including urinary tract infections, coronary conditions, diabetes, hypertension, and dementia were associated with a higher likelihood of treatment change. Understanding the factors associated with treatment change may inform ways to improve management of PDP in the U.S. LTC setting.